- Home
- About us
About Us
Brains Bioceutical is the global benchmark for pharmaceutical-grade cannabinoid innovation, operating one of the world's only EU-GMP certified facilities capable of producing validated APIs at commercial scale. From our 25,000 sq. ft. UK manufacturing center and Vancouver headquarters, we supply the highest-purity cannabinoid APIs to pharmaceutical, nutraceutical, and veterinary partners across six continents.
Redefining Cannabinoid Medicine at Pharmaceutical Scale
The cannabinoid pharmaceutical sector is experiencing unprecedented growth, with market opportunities exceeding $200 billion across APIs, therapeutics, nutraceuticals, and animal health applications. As regulatory frameworks mature and clinical evidence expands, cannabinoids are transitioning from experimental compounds to validated pharmaceutical ingredients.
Brains Bio stands uniquely positioned to capture this transformation. Our cash-flow positive operations, validated partnerships with industry leaders, and multiple near-term regulatory catalysts create a compelling platform for sustained growth as the market evolves from early adoption to mainstream pharmaceutical acceptance.
- Pharmaceutical APIs Market: $50+ billion by 2025
- Therapeutic Applications Market: Multi-billion dollar indications including $8.4B Opioid Use Disorder market
- Nutraceuticals Market: $89 billion by 2026
- Animal Health Market: $1.1 billion by 2025
Company Verticals
Brains Bioceutical is the global benchmark for pharmaceutical-grade cannabinoid innovation, operating one of the world's only EU-GMP certified facilities capable of producing validated APIs at commercial scale. From our 25,000 sq. ft. UK manufacturing center and Vancouver headquarters, we supply the highest-purity cannabinoid APIs to pharmaceutical, nutraceutical, and veterinary partners across six continents.
Our breakthrough solid THC innovation and unmatched regulatory expertise have established Brains as the trusted partner for companies seeking to unlock cannabinoid therapeutics' full potential.
With over 500 commercial GMP batches produced and contracted revenue through 2030, Brains Bio operates with the financial strength and manufacturing excellence that pharmaceutical leaders demand.
Senior Leadership Team
Our executive team combines decades of experience from GSK, Pfizer, Biogen, Vertex, and Novartis with specialized cannabinoid expertise, creating unmatched capability to navigate complex regulatory pathways and deliver breakthrough therapeutic solutions. This depth of pharmaceutical leadership distinguishes Brains Bio as the only cannabinoid company with the regulatory expertise and manufacturing excellence required to succeed in highly regulated global markets.
Barinder Bhullar
Senior VP, Corporate Affairs
Strategic Partnership Portfolio
Our partnerships with industry leaders validate our position as the cannabinoid sector's most trusted supplier. Through our exclusive global partnership with global multinationals, we're unlocking therapeutic potential in early-stage drug development. Our multi-year agreement with Vitabiotics, the UK's number one vitamin company with 27% market share and distribution to over 100 countries, demonstrates our nutraceutical market leadership.
Irreplaceable Market Position
Brains Bioceutical represents a rare combination of regulatory validation through EU-GMP certification and global partnerships, scientific credibility via 30+ clinical trials and 500+ commercial batches, revenue diversification across pharmaceutical, nutraceutical, and animal health markets, and defensive moats through manufacturing excellence and exclusive partnerships.
From breakthrough APIs to regulatory firsts, Brains Bioceutical delivers the pharmaceutical excellence that transforms cannabinoid potential into patient outcomes.
